Clinical Trials Logo

Hydrocephalus, Normal Pressure clinical trials

View clinical trials related to Hydrocephalus, Normal Pressure.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06428734 Recruiting - Hydrocephalus Clinical Trials

Clinical Outcome in Patients With INPH

Start date: May 15, 2024
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to determine the clinical spectrum and natural progression of idiopathic normal pressure hydrocephalus (iNPH ) and related disorders in a prospective single center study, identify digital, imaging and molecular biomarkers that can assist in diagnosis and therapy development and study the etiology and molecular mechanisms of these diseases.

NCT ID: NCT06083233 Recruiting - Brain Damage Clinical Trials

Role of Brain Specific Biomarkers in Hydrocephalus

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Normal pressure hydrocephalus (NPH) is a neurodegenerative disease of unclear etiology characterized by a clinical trias named after the neurosurgeon Hakim. It includes cognitive impairment (dementia), gait disturbance, and urinary incontinence. These symptoms, which frequently occur in the elderly population, often overlap with the symptoms of "other" neurodegenerative diseases, especially Alzheimer's disease and other (pre)senile dementias. To distinguishing NPH from "other" dementias is crucial in determining whether a patient will benefit from a surgical procedure (ventriculoperitoneal shunt placement) or not. At the same time, the options for assessing the patient's condition's progression and distinguishing between the progression of neurodegeneration in a broader sense or malfunction of the drainage system are very limited. Therefore, the role of a biomarker that could meet these expectations mentioned above is highly desirable.

NCT ID: NCT05910944 Recruiting - Hydrocephalus Clinical Trials

European Study of Prodromal iNPH

STOP iNPH
Start date: November 1, 2023
Phase:
Study type: Observational

To investigate if progression from prodromal into symptomatic NPH can be predicted from advanced neuroimaging, biomarkers in cerebrospinal fluid (CSF) and plasma and investigate the unknown mechanisms causing deterioration by investigating longitudinal changes in the above-mentioned variables. Three different cohorts with both asymptomatic and symptomatic patients as well as healthy controls will be investigated over time, both without intervention and before and after shunt surgery.

NCT ID: NCT05679934 Recruiting - Clinical trials for NPH (Normal Pressure Hydrocephalus)

The Effects of Exercise on Gait Characteristics, Balance, and Performance in Patients With Normal Pressure Hydrocephalus

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to investigate effect of exercise program on balance, gait and performance in patients with normal pressure hydrocephalus applied with lumbar puncture. The main question it aims to answer are: - Home based exercise program effective on balance, gait and performance - Telerehabilitation exercise program effective on balance, gait and performance Researchers will compare home based exercise group, telerehabilitation group and control group to see if difference in terms of balance, gait and performance

NCT ID: NCT05397106 Recruiting - Brain Tumor Clinical Trials

Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve

Start date: January 24, 2023
Phase:
Study type: Observational

Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.

NCT ID: NCT05250505 Recruiting - Hydrocephalus Clinical Trials

Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Start date: March 10, 2022
Phase: N/A
Study type: Interventional

The eShunt System includes proprietary delivery componentry and the eShunt Implant, a permanent implant deployed in a minimally invasive, neurointerventional procedure. The eShunt Implant is designed to mimic the function of the arachnoid granulations by draining excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.

NCT ID: NCT05232838 Recruiting - Hydrocephalus Clinical Trials

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Start date: April 20, 2022
Phase: N/A
Study type: Interventional

The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.

NCT ID: NCT05081128 Recruiting - Clinical trials for Idiopathic Normal Pressure Hydrocephalus (INPH)

Efficacy in iNPH Shunting (PENS) Trial

PENS
Start date: May 18, 2022
Phase: N/A
Study type: Interventional

The Placebo-Controlled Efficacy in Idiopathic Normal Pressure Hydrocephalus (iNPH) Shunting (PENS) trial is a multi-center blinded, randomized, placebo-controlled design investigation of cerebrospinal fluid (CSF) shunt surgery to study the shunt efficacy in iNPH patients.

NCT ID: NCT04998175 Recruiting - Clinical trials for Idiopathic Normal Pressure Hydrocephalus

Multi-omics Research of Idopathic Normal Pressure Hydrocephalus (iNPH)

Start date: September 15, 2020
Phase: N/A
Study type: Interventional

The research is designed to study the prognostic factors of ventriculoperitoneal (VP) shunt for iNPH by multi-omics research

NCT ID: NCT04975269 Recruiting - Clinical trials for Idiopathic Normal Pressure Hydrocephalus (INPH)

Acetazolamide Trial in Normal Pressure Hydrocephalus

DRAIN
Start date: February 17, 2022
Phase: Phase 2
Study type: Interventional

A pharmacological treatment to patients with normal pressure hydrocephalus (NPH) is missing. The aim is to investigate if acetazolamide given to patients with NPH improves gait function and study the pathophysiological mechanisms leading to reduced symptoms. Patients will be randomized to acetazolamide or placebo and duration of treatment will be from diagnosis to the day of shunt surgery. Target dose is 500 mg/day. Study design is a double-blind randomized controlled trial and the plan is to include 42-50 patients. The study is investigator-initiated without financial sponsorship from the industry.